Orizuru Therapeutics
↗Kyoto/Fujisawa, Japan
Orizuru Therapeutics is a regenerative medicine biotech company founded in 2021 as a spinout from a collaboration between Takeda Pharmaceutical Company and Kyoto University's Center for iPS Cell Research and Application (CiRA). The company specializes in translating induced pluripotent stem cell (iPSC) technology into clinical-stage cell therapy products. Orizuru's core focus is developing cell therapies for unmet medical needs, particularly severe type 1 diabetes and heart failure. The company is leveraging proprietary iPSC differentiation and manufacturing technology to create clinical-grade therapeutic products.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Regenerative Medicine / Cell Therapy
SIZE & FINANCIALS
Employees:51-200
Founded:2021
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$103M (>¥10 billion)
Investors:Japan Growth Capital Investment Corporation, Nomura SPARX Investment, T1D Fund, Medipal Holdings, MUFG Bank, Kyoto University Innovation Capital Co., Ltd., Takeda Pharmaceutical Company Limited, SMBC Venture Capital Co., Ltd., Sumitomo Mitsui Finance and Leasing Company Co.
PIPELINE
Stage:Clinical Phase 1/1b
Lead Drug Stage:OZTx-410 in Phase 1/1b clinical trial (first patient implanted April 2025)
Modalities:Cell therapy, iPS cell-derived products, Cell sheets
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Kyoto University (CiRA - Center for iPS Cell Research and Application), Takeda Pharmaceutical Company, Kyoto University Hospital (clinical trial site), PeptiGrowth Inc. (peptide development collaboration)
COMPETITION
Position:Emerging
Competitors:Allogene Therapeutics, Editas Medicine, CRISPR Therapeutics, Sangamo Therapeutics, Other cell therapy and regenerative medicine companies
LEADERSHIP
Key Executives:
Kenji Nonaka - President, Representative Director, Chief Executive Officer
Yu Yoshimura - Chief Financial Officer
Shinji Ogawa - Vice President, Chief Operating Officer, Board Member
Scientific Founders:Takeda Pharmaceutical Company, Kyoto University CiRA
Board Members:Shinji Ogawa
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Orizuru Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Orizuru Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.